Loading
CorMedix Inc. is a biopharmaceutical company engaged in the development and commercialization of medical treatments for the prevention and care of infectious and inflammatory conditions, serving markets both in the United States and internationally. Its leading product candidate, DefenCath/Neutrolin, represents a novel anti-infective solution. This treatment aims to diminish and avert catheter-related infections and blood clots in patients who utilize central venous catheters for medical procedures such as hemodialysis, total parenteral nutrition, and oncology care. Incorporated in 2006, the company initially operated as Picton Holding Company, Inc. until officially adopting the name CorMedix Inc. in January 2007. Its corporate headquarters are located in Berkeley Heights, New Jersey.
Previous close
$8.13
−$0.05 · -0.61%
After-hours
$8.29
+$0.16 · +1.97%
Sep 9, 7:30 PM ET
Regular session · ET · Market data may be delayed.
CorMedix Inc. is a biopharmaceutical company engaged in the development and commercialization of medical treatments for the prevention and care of infectious and inflammatory conditions, serving markets both in the United States and internationally. Its leading product candidate, DefenCath/Neutrolin, represents a novel anti-infective solution. This treatment aims to diminish and avert catheter-related infections and blood clots in patients who utilize central venous catheters for medical procedures such as hemodialysis, total parenteral nutrition, and oncology care. Incorporated in 2006, the company initially operated as Picton Holding Company, Inc. until officially adopting the name CorMedix Inc. in January 2007. Its corporate headquarters are located in Berkeley Heights, New Jersey.
Day range
Current $8.13
52-week range
Current $8.13
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
87
Deep Value
Sentiment
66
Bullish
Risk
60
Elevated Risk
Momentum
42
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
CorMedix Inc. is a biopharmaceutical company engaged in the development and commercialization of medical treatments for the prevention and care of infectious and inflammatory conditions, serving markets both in the United States and internationally. Its leading product candidate, DefenCath/Neutrolin, represents a novel anti-infective solution. This treatment aims to diminish and avert catheter-related infections and blood clots in patients who utilize central venous catheters for medical procedures such as hemodialysis, total parenteral nutrition, and oncology care. Incorporated in 2006, the company initially operated as Picton Holding Company, Inc. until officially adopting the name CorMedix Inc. in January 2007. Its corporate headquarters are located in Berkeley Heights, New Jersey.
Day range
Current $8.13
52-week range
Current $8.13
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI16.77M0.00%2.3T USD0.03%$375.56-0.54%
iShares Russell 2000 ETFIWM16.17M0.02%80.51B USD0.19%$290.64-1.37%
Avantis U.S. Small Cap Value ETFAVUV13.46M0.04%31.45B USD0.25%$124.31-0.81%
State Street SPDR S&P Pharmaceuticals ETFXPH6.64M1.07%616.33M USD0.35%$69.32-1.51%
Vanguard Extended Market ETFVXF6.3M0.01%93.7B USD0.05%$238.67-1.11%
iShares Russell 2000 Value ETFIWN5.9M0.04%14.61B USD0.24%$220.48-1.02%
Pacer US Small Cap Cash Cows ETFCALF5.16M0.13%3.96B USD0.59%$55.70-0.73%
Vanguard Russell 2000 ETFVTWO3.15M0.02%17.4B USD0.06%$117.51-1.37%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMAvantis U.S. Small Cap Value ETFAVUVState Street SPDR S&P Pharmaceuticals ETFXPHVanguard Extended Market ETFVXFiShares Russell 2000 Value ETFIWNPacer US Small Cap Cash Cows ETFCALFVanguard Russell 2000 ETFVTWOAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
